Incannex commences participant screening in Phase 2 DReAMzz study of IHL-42X for obstructive sleep apnea

Incannex Healthcare Inc.

First clinical sites approved and actively screening participants for DReAMzz Phase 2 dose confirmation study of IHL-42X.
IHL-42X has FDA Fast Track designation, supporting potentially expedited regulatory pathway.
Prior Phase 2 data showed up to 83% reduction in AHI and significant improvements in patient-reported outcomes.
No FDA-approved oral pharmaceutical therapies currently available for OSA, affecting ~1 billion people globally.
Study designed to optimize dosing profile and strengthen regulatory package ahead of planned Phase III development.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.